Plaintiffs file third amended US complaint against Biogen over Tecfidera
MLex Summary: Plaintiffs filed their third amended US class action complaint accusing Biogen of unlawfully impairing competition from generic versions of its brand-name drug Tecfidera, which is used to treat multiple...To view the full article, register now.
Already a subscriber? Click here to view full article